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Keywords:
Novel nanomaterials are being developed to improve diagnosis and therapy of diseases through effective
delivery of drugs, biopharmaceutical molecules and imaging agents to target cells in disease sites. Such
diagnostic and therapeutic nanomaterials, also termed “nanomedicines”, often require site-speciﬁc cellular
entry to deliver their payload to sub-cellular locations hidden beneath cell membranes. Nanomedicines can
employ multiple pathways for cellular entry, which are currently insufﬁciently understood. This review, ﬁrst,
classiﬁes various mechanisms of endocytosis available to nanomedicines including phagocytosis and
1. Introduction: Cellular entry of nanomedic
2. Tools to dissect intracellular trafﬁcking
3. Phagocytosis . . . . . . . . . . . . .
. . .pinocytosis through clathrin-dependent and clathrin-independent pathways. Second, it describes the current
experimental tools to study endocytosis of nanomedicines. Third, it provides speciﬁc examples from recent
literature and our own work on endocytosis of nanomedicines. Finally, these examples are used to ascertainEndocytosis
Nanomedicines
Nanoparticles
Intracellular trafﬁcking
Caveolae
Clathrin
Contents1) the role of particle size, shape, material composition, surface chemistry and/or charge for utilization of a
selected pathway(s); 2) the effect of cell type on the processing of nanomedicines; and 3) the effect of
nanomaterial-cell interactions on the processes of endocytosis, the fate of the nanomedicines and the
resulting cellular responses. This review will be useful to a diverse audience of students and scientists who
are interested in understanding endocytosis of nanomedicines.
© 2010 Elsevier B.V. All rights reserved.
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1. Introduction: Cellular entry of nanomedicines to determined locations inside cells [7]. Consequently, the interest to
intracellular trafﬁcking of nanomaterials has skyrocketed.A new era of nanomedicine that uses devices of nanoscale size to
address urgent needs for improved diagnosis and therapy of diseases is
being etched in the 21st century. Polymeric micelles, quantum dots,
liposomes, polymer-drug conjugates, dendrimers, biodegradable nano-
particles, silica nanoparticles, etc. are few examples of nanoparticulate
materials researched in laboratories, undergoing preclinical develop-
ment, or already used in the clinic [1–6]. These nanomaterials,
collectively called “nanomedicines”, can deliver low molecular mass
compounds, proteins and recombinant DNAs to focal areas of disease or
to tumors to maximize clinical beneﬁt while limiting untoward side
effects. Such nanomedicines are also expected to drastically improve
early diagnosis throughmolecular imaging techniques. A quintessential
feature of such modalities is their ability for site-speciﬁc delivery, not
only to the desired organ, but also to a targeted sub-cellular
compartment. Hence, a new paradigm for drug delivery and nanome-
dicine requires nanomaterials to differentially interact with the surface
of their target cells and undergo intracellular trafﬁcking thatwould leadFig. 1. Different mechanisms of endocytosis. There are multiple pathways for cellular entry o
evolving [11,12]. In all cases the initial stage of endocytosis proceeds from the plasmamembr
The second stage often involves sorting of the cargo through endosomes. It is followed by
extracellular milieu or delivered across cells (not shown). The ﬁgure is a simpliﬁed represent
phagocytosis and CME are presented in Figs. 3 and 5. Abbreviations are: CCV, clathrin coat
compartment; GPI, glycophosphatidylinositol, MVB, multivesicular body.A nanoparticle placed in the external milieu of a cell can interact with
the exterior of the plasmamembrane, which can lead to this nanoparticle
entry inside the cell through a process termed “endocytosis” (Fig. 1).
Endocytosis involves multiple stages. First, the cargo is engulfed in
membrane invaginations that are pinched off to form membrane-bound
vesicles, also known as endosomes (or phagosomes in case of
phagocytosis). Cells contain heterogeneous populations of endosomes
equipped with distinct endocytic machinery, which originate at different
sites of the cell membrane. Second, the endosomes deliver the cargo to
various specialized vesicular structures, which enables sorting of cargo
towards different destinations. Finally, the cargo is delivered to various
intracellular compartments, recycled to the extracellular milieu or
delivered across cells (a process known as “transcytosis” in polarized
cells). Generally, endocytosis can be divided into two broad categories—
phagocytosis (theuptakeof largeparticles) andpinocytosis (theuptakeof
ﬂuids and solutes). Phagocytosis was originally discovered by Ilya
Mechnikov as a process by which macrophages engulf particles as largef particles and solutes. The picture of endocytosis trafﬁcking is actively researched and
ane portals of cellular entry and involves engulfment of cargo into intracellular vesicles.
the ﬁnal stage during which the cargo is delivered to its ﬁnal destination, recycled to
ation of complex trafﬁcking mechanisms and their cross-talks. More details for stages of
ed vesicles, CLIC, clathrin-independent carriers; GEEC, GPI-anchored protein-enriched
as 20 µm [8]. This process is characteristic of specialized professional
phagocytes, such as, macrophages, neutrophils, monocytes and dendritic
endocytosis markers and structures or 2) exclusion of speciﬁc
endocytosis mechanisms by inhibitors of endocytosis or cell mutants.
Fig. 2. Classiﬁcation of endocytosis based on endocytosis proteins that are involved in
the initial entry of particles and solutes.
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forms depending on the cell origin and function. Several different
classiﬁcations of pinocytosis have been proposed. The most recent
approach is based on the proteins involved in different endocytic
pathways (Fig. 2). In this approach pinocytosis is classiﬁed as clathrin-
dependent endocytosis (also known as clathrin-mediated endocytosis
(CME)) and clathrin-independent endocytosis [9]. The clathrin-indepen-
dent pathways are further classiﬁed as 1) caveolae-mediated endocytosis,
2) clathrin- and caveolae-independent endocytosis and 3) macropinocy-
tosis. Clathrin- and caveolae-independent pathways are sub-classiﬁed as
Arf6-dependent, ﬂotillin-dependent, Cdc42-dependent and RhoA-de-
pendent endocytosis [10]. Another classiﬁcation of endocytosis, based on
material interaction with the cellular membrane (receptor-mediated,
adsorptive, ﬂuid phase), has also been used to describe cellular entry of
nanomaterials. However, this classiﬁcation is less precise and often
mistakenly used interchangeably with the previously described classiﬁ-
cation (e.g., receptor-mediated endocytosis is sometimes confused with
CME). We, therefore, urge the nanomedicine community to utilize the
classiﬁcation based on endocytosis proteins that is being actively
researched and have recently emerged in the endocytosis ﬁeld (Fig. 2).
This papers overviews different endocytosis pathways utilized by
various nanomaterials to enter cells and attempts tomake some general
conclusions about the preferred trafﬁcking routes based on the
nanomaterial structure and properties. We brieﬂy describe phagocyto-
sis and focus in detail on various pinocytosis mechanisms including
clathrin-dependent and clathrin-independent pathways. The current
experimental tools to study endocytosis of nanomaterials are discussed
followed by speciﬁc examples from recent literature and our ownwork
on selected nanomaterials that have shown to employ different
pathways. These examples are used to ascertain several key questions,
such as: i) whether particle size, shape, material composition, surface
chemistry and/or charge are responsible for employment of a selected
pathway; ii) how are nanomaterials processed in different cell types;
and iii) how do nanomaterial-cell interactions inﬂuence cell trafﬁcking
andwhether such interactions can impactnanomaterial fate andcellular
responses? Of course, in view of great diversity of nanomaterials,
multiplicity and complexity of cellular pathways, and often missing
comprehensive experimental data our generalization cannot be
complete. Nevertheless, we believe that our analysis with help both
established nanomedicine investigators and thosewho are just entering
this exciting ﬁeld to understand its current state.
2. Tools to dissect intracellular trafﬁcking
Most current methods to study intracellular trafﬁcking of nanoma-
terials involve either 1) colocalization of nanomaterials with speciﬁcIn case of colocalization studies different markers can be used. For
example, in so-called “pulse-chase” design, proteins, such as transferrin
or cholera toxin B (CTB), with known trafﬁcking pathways are exposed
to cells simultaneously or before the nanomaterial (“pulse”) and their
inclusion or exclusion from the same vesicles is detected at different
time points (“chase”). The most widespread current method for
detection involves attaching different ﬂuorescent probes to the protein
and nanomaterial that allows analyzing distribution of color or
ﬂuorescence resonance energy transfer (FRET) throughout the cell
compartments. The advantage of such approach is that it allows using
live cell imaging by confocal microscopy, which arguably causes least
artifacts. The disadvantage is that such endocytosis markers are rarely
selective with respect to speciﬁc trafﬁcking pathways and may utilize
different endocytosis mechanisms in different cell types. Therefore, as
an alternative or supplementary approach, cells can be transfectedwith
constructs containing proteins that reside in speciﬁc endocytosis
vesicles or intracellular organelles, which are fused with ﬂuorescent
proteins, such as theGreen Fluorescent Protein (GFP). Examples include
rab5 in early endosomes [13], caveolin-1 in caveolae [14], human Golgi-
resident enzyme N-acetylgalactosaminyltranferase-2 in Golgi [15],
lysosomal association protein 1 (Lamp1) in lysosomes [16], signal
sequence of calreticulin and endoplasmic reticulum (ER) retention
signal KDEL in ER [17], leader sequence of E1 alpha pyruvate
dehydrogenase in mitochondria [18], myristoyl/palmtoylation se-
quence from Lck tyrosine kinase in plasma membrane [19] and actin
or tubulin in cytoskeleton [20]. In addition to the fusion proteins there
are a variety of small molecular mass probes, which can stain speciﬁc
cellular organelles. The examples of such probes include weakly basic
amines such as Lysotracker™ that selectively accumulate in lysosomes,
ﬂuorescently labeled glibenclamide that binds to the sulphonylurea
receptors of ATP-sensitive K+ channels in ER, the mitochondrial dye
MitoTracker™ [21] and others. Importantly, colocalization of nanoma-
terialswith fusionproteins andmolecular probes can be also explored in
live cells. Another way of studying colocalization is immunocytochem-
istry applied to ﬁxed cells. This method allows employing speciﬁc
antibodies to different proteins present along the endocytic vesicles and
organelles. It considerably supplements the available fusion proteins
and molecular probes. Furthermore, in this case the detection can use
ﬂuorescent probes, enzymes, gold nanoparticles andmany other labels,
which also broadens the spectrum of available visualization tools. Apart
from confocal microscopy, the electron microscopy is also highly useful
as it allowsvisualizingnanomaterials coupledwithelectrondense labels
in different vesicular structures under very high resolution [22]. Atomic
ForceMicroscopy (AFM)has also been used recently to demonstrate the
interactions of nanomaterials with the cell membrane [23].
Exclusion of speciﬁc endocytosis mechanisms is a distinct and
powerful technique to elucidate endocytosis. This can be achieved, for
example, using various pharmacologic inhibitors of endocytosis that
include chemical or biological agents [24,25]. Examples of chemical
inhibitors include K+ depletion of sucrose for CME, methyl-beta-
cyclodextrin (MβCD) and other cholesterol depletory compounds for
caveolae, as well as other compounds described in Table 1. One issue
with chemical inhibitors is that they are rarely selective and often
disturb multiple endocytosis pathways [25]. Therefore, it is essential
to utilize such inhibitors in combination with endocytosis markers as
positive controls and other methods described above to validate the
inhibitory mechanism and effective inhibitor concentration in the
particular cell types. As an alternative the use of siRNA that can knock-
down speciﬁc endocytic proteins is becoming increasingly popular
[14]. Similarly, the dominant negative transfected mutants have been
used extensively to exclude speciﬁc endocytosis pathways [26,27].
Some of such mutants are listed in Table 1. In the case of mutants an
additional advantage is the possibility to co-express GFP or other
reporter, which allows visualizing the transfected cell population in
live cells. In this case the non-transfected cells serve as an internal
control. It is useful also to employ in parallel both the siRNA gene
immunoglobulins or complement molecules adsorbed at the particle
[32]. Other receptors that may play a role in phagocytosis of
Table 1
Main pathways of pinocytosis are presented along with some examples of their cargoes, endocytic proteins and biological and chemical inhibitors. Abbreviations are: AP2, adaptor
protein-2; AP180, adaptor protein-180; Arf (1 or 6), ADP-ribosylation factor; Cdc42, cell division control protein 42; CTB, cholera toxin B; CytoD, cytochalasin D; γc-cytokine
receptor, cytokine receptor common gamma chain; DN, dominant negative; FCεR1, fragment crystallizable region epsilon receptor-1;GPCR, G-protein coupled receptors; GPI,
glycophosphatidylinositol; IL2Rβ, interleukin-2 receptor beta; KD, knock-down; LatA, latrunculin A; MβCD, methyl-beta-cyclodextrin; MHC, major histocompatibility complex;
M6P, mannose-6-phosphate; PP2, (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine); Rab5, ras-like in rat brain; Rac1, ras-related C3 botulinum toxin substrate
1; RhoA, ras homolog gene family, member A; RTKs, receptor tyrosine kinases; Src, sarcoma (protooncogenic tyrosine kinase), SNX9, sorting nexin-9; SV40, simian virus-40; and TfR,
transferrin receptor.
Pinocytosis
pathways
Implicated cargoes Endocytic proteins Dynamin
dependence
Inhibitor(s)
Chemical Biological
CME RTKs, GPCRs, TfR, M6P,
anthrax toxin
Clathrin, AP2, epsin, SNX9, actin,
amphiphysin, Rab5 and many
others
Yes Hypertonic sucrose, K+ depletion,
chlorpromazine, actin polymerization
inhibitors (CytoD, LatA)
AP180 DN, dynamin2 DN
Caveolae-mediated
endocytosis
CTB, SV40, modiﬁed albumin,
GPI-anchored protein
Caveolin, cavin, Src, actin, PKC
(many signaling proteins localize
on caveolae)
Yes Cholesterol depletors (e.g. mβCD, Filipin),
genistein, PP2 (src kinase family inhibitor),
actin polymerization inhibitors
dynamin2 DN, cav1 DN, cav1
KD
Arf6 MHC class I proteins,
protectin, carboxypeptidase
Arf6 No Cholesterol Depletors, genistein, actin
polymerization inhibitors
Arf6 DN
Flotillin CTB, protectin, proteoglycans Flotillin1 and 2, other proteins
unclear
No Cholesterol depletors, genistein, actin
polymerization inhibitors
Cdc42 Fluid phase markers, CTB,
GPI-anchored protein
Cdc42, Arf1 Unclear Cholesterol depletors, genistein, actin
polymerization inhibitors
Cdc42 DN, Clostridium toxin B
(RhoA GTPase inhibitor)
RhoA IL2Rβ, FcεR1, γc-cytokine
receptor
RhoA, Rac1 Unclear Cholesterol depletors, genistein, actin
polymerization inhibitors
RhoA, Clostridium toxin B
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artifacts associated with each method. One concern, however, with
both siRNA and mutant-based techniques is that the transfection
agents used to deliver siRNA or gene into cells may also disturb the
trafﬁcking pathways present in naïve cells. This can be overcome by
utilizing stably transfected cells or knock-out cell lines derived from
knock-out animals. An example of such knock-out cells are caveolae-
deﬁcient ﬁbroblasts derived from caveolae −/− mice [28].
The cells with excluded endocytosis mechanisms are studied along
with the normal cells using a variety of techniques allowing
determining intracellular trafﬁcking of nanomaterials. For example,
confocal microscopy can be performed after exposure of cells to
chemical and biological inhibitors and compared with that of the
untreated cells [21]. The confocal microscopy has been coupled with
3D Z-stack imaging analysis to obtain exact location of the studied
materials. The uptake of nanomaterials can be also quantiﬁed by ﬂow
cytometery, ﬂuorescent microscopy or simple radioactivity sampling
[29]. Most recently, multiple particle tracking has been used by
several investigators to monitor the dynamics of the endocytosis of
various nanomaterials in different cells [30]. However, a thorough and
conclusive analysis must include multiple approaches to unambigu-
ously dissect intracellular trafﬁcking mechanisms.
3. PhagocytosisFig. 3. Stagesofphagocytosis ofparticles. 1)Particlesundergorecognition in thebloodstream
through opsonization i.e. adsorption of proteins (immunoglubulins (Ig) G (and M),
complement components (C3, C4, C5); blood serumproteins (including laminin,ﬁbronectin,
etc.). 2) Opsonized particles attach onto the cellmembrane through receptors present on the
cell surfaceof aphagocyte. 3)Theparticles are ingested intophagosomes. 4)Thephagosomes
mature, fuse with lysosomes and become acidiﬁed, leading to the enzyme-rich phagolyso-
somes where the particles are prone to degradation.As mentioned already phagocytosis occurs primarily in professional
phagocytes, like macrophages, monocytes, neutrophils and dendritic
cells. There are suggestions that some other types of cells, referred to as
nonprofessional phagocytes, such as ﬁbroblasts, epithelial and endo-
thelial cells, may also display some phagocytic activity, but to a much
lower extent [31]. Altogether, the phagocytic pathway of cellular entry
consists of three distinct steps (Fig. 3): 1) recognition of the particles by
opsonization in the bloodstream; 2) adhesion of the opsonized particles
onto the cell membrane; and 3) ingestion of the particle by the cells.
Opsonization of nanoparticles occurs through adsorption of proteins,
such as immunoglubulins (Ig)G (andM), complement components (C3,
C4, C5), blood serum proteins (including laminin, ﬁbronectin, etc.) and
others. The opsonized particle then attaches to the macrophage surface
through speciﬁc receptors. For example, Fc receptor (FcR) or comple-
ment receptors (CR) can bind respectively to the constant fragment ofnanoparticles include mannose/fructose and scavenger receptors
[32,33]. The receptor–ligand interaction leads to signal cascades,
which result in actin rearrangement and formation of a phagosome.
The phagosome may have different sizes depending of the size of the
particles, which can range from as little as few hundred nanometers to
dozens of microns [31]. Examples were described with murine bone
marrow-derivedmacrophages of nearly 14 µm ingesting IgG-opsonized
latex beads greater than 20 µm in diameter [34]. Phagosome and its
contents undergo maturation through a series of fusion and ﬁssion
events, which lead to the transfer of the cargo to the late endosomes and
ultimately lysosomes to form a phagolysosome.
A recent study by Champion et al. described the striking effect of the
shape of particles on phagocytosis in alveolar rat macrophages [35].
They have prepared polystryrene (PS) based particles of more than
twenty shapes including spheres, rectangles, rods, worms, oblate
ellipses, elliptical disks (PS) and UFO-like [35]. The particle sizes were
primarily 1 to about 10 µm. However, the size was not a determining
factor in phagocytosis [36]. All particle shapes independently of their
sizes were capable of initiating phagocytosis in at least one orientation.
However, unexpectedly, the crucial role in phagocytosis was played by
the local particle shape at the point where the particle was attached to
the macrophage [35]. For example, a macrophage attached to a sharper
via the Tf receptor. These proteins are now commonly used as markers
of CME. Other functions of CME include down-regulation of cell
Fig. 4. Effect of particle geometry on phagocytosis. The entry of a nanoparticles inside
macrophages depends on the angle between the membrane normal at the point of initial
contact and the line deﬁning the particle curvature at this point (Ω). The internalization
velocity is positive atΩ≤45°, which indicates that the particle undergoes internalization.
As the angle exceeds critical value (≈45°) the internalization velocity is zero, the
macrophages lose the ability to entrap particles and start spreading over the particle.
Fig. 5. Schematic representation of CME. 1) The assembly proteins, AP-2 and AP180 are
targeted to the plasma membrane where they mediate clathrin assembly. Upon that
clathrin triskelions polymerize into a polygonal lattice, which helps to deform the plasma
membrane into a coated pit. 2) Dynamin, a multidomain GTPase, is recruited to the necks
of coated pits, where it assembles into a spiral collar. Upon hydrolysis of GTP dynamic
collar promotes scission of themembrane and release of the vesicle known as CCV. 3) The
next step involves uncoating of CCV and formation of an early endosomes, which are then
routed towards the lysosomes as shown in Fig. 1. 4) The coat constituents are recycled for
reuse.
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contrast, a macrophage attached to a dull side would not internalize the
sameellipse formanyhours (Fig. 4). Sphereswere internalized fromany
point of attachment independently of their size. Although, particle size
played amuch lesser role in the initiation of the phagocytosis it could of
course affect its completion especially when the particle volume
exceeded that of a cell.
The effect of the geometry in phagocytosis was quantiﬁed by
measuring the angle between the membrane normal at the point of
initial contact and the line deﬁning the particle curvature at this point
[36]. If this angle exceeded some critical value (45°) the macrophages
would lose theability toentrapparticles andattach to theseparticles in a
process similar to spreading (Fig. 4). The authors suggested that the
shape of the particle at the point of attachment deﬁned the complexity
of actin structures that would need to be rearranged to allow
engulfment. Above the critical point the necessary actin structures
could not be created and the macrophages would switch to the
spreading behavior. Altogether, this eloquent study clearly demonstrat-
ed the relationship between cellular transport by phagocytosis and
physical properties of the phagocytosed materials. Further examples of
different nanomaterials, which utilize phagocytosis can be found in a
recent review by Hillaireau et al. [31].
4. Clathrin-dependent endocytosis
CME is the “classical route” of cellular entry, which is present and
inherently active in all mammalian cells. It is responsible for uptake of
essential nutrients like cholesterol carried into cells by low density
lipoprotein (LDL) via the LDL receptor, or iron carried by transferrin (Tf)signaling by internalization and degradation of receptors andmaintain-
ing cellular homeostasis, for example, by trafﬁcking ion pumps [9,12].
Mechanistically, CME involves engulfment of receptors associated
with their ligands to a coated pit. The coated pit forms due to
polymerization of a cytosolic protein called clathrin-1, which also
requires assembly proteins like AP180 and AP-2. The assembled vesicle
(ca. 120 nm) is pinched off from the plasma membrane by a small
GTPase, dynamin [37] (Fig. 5). Various accessory proteins like
amphiphysin, Eps15 and intersectin, have been shown to act as scaffolds
that connect the endocytic machinery with actin cytoskeleton [38,39].
Actin deﬁnes spatial regulation and movement of the endocytic vesicle
towards the interior of the cells.Within cells the clathrin coat is shed off
and the vesicles fusewith the early endosomeswhere they are sorted to
late endosomes/lysosomes, to trans-Golgi network or to the recycling
endosomes to be transported back to plasma membrane [40].
While there are multiple and sometimes conﬂicting reports on the
nanomaterials trafﬁcking pathways, there are few examples in which
CME appears to be deﬁned as the most prominent mechanism for the
cellular entry. These examples are described below.
4.1. Poly(ethylene glycol)-polylactide nanoparticles
The biodegradable nanoparticles made of D,L-polylactide (PLA) and
poly(ethylene glycol-co-lactide) (PEG-co-PLA) blends are widely
explored for drug delivery [41,42]. Due to the presence of the partially
hydrolyzed PLA the surface of these nanoparticles is usually
negatively charged but can be altered by cationic surfactants such as
stearylamine. A recent study, examined the effect of such modiﬁca-
tions on the uptake of the nanoparticles (around 100 nm) in ﬁbroblast
and epithelial cells [41,42]. In both cell types the cationic particles
were more readily accumulated in cells compared to anionic particles.
However, the pathways of their entry depended on the cell type.
In the polarized MDCK epithelial cells, which are normally devoid
of caveolae on the apical surface [43,44], the nanoparticles used
CME independently of their charge. In contrast, in non-polarized HeLa
cervical cancer cells the anionic particles used multiple pathways
(CME and caveolae-mediated), while cationic particles appeared to be
restricted to CME as well as to macropinocytosis. Interestingly, the
nanoparticles' charge also determined their intracellular fate. In
MDCK cells the cationic particles were routed for transcytosis, while
the anionic particles reached the lysosomes [41,42]. This example
clearly shows that the entry and subsequent trafﬁcking of the
nanoparticles can depend both on the cell type and the particle charge.
the ligand alone [54]. For example, quantum dots (QDs) (ca. 50 nm)
modiﬁed with Tf utilized CME as the initial stage of entry, however, in
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A close example is a nanoparticle made of PLGA, a biodegradable
synthetic material approved by the United States Food and Drug
Administration (FDA) for therapeutic use [45]. The cellular transport
of such nanoparticles was also shown to be both cell type and surface
charge dependent [23]. In this case the nanoparticles were relatively
large (ca. 300 nm) and heterogeneous (polydispersity index 0.2),
which obviously complicated interpretations of their cellular uptake.
Nevertheless, the cell dependence of the uptake was shown using
basic PLGA nanoparticles, which are negatively charged. In the
vascular smooth muscle cells (VSMCs) these particles entered
predominantly through the CME, however, in rat corneal epithelial
cells they utilized the clathrin- and caveolae-independent pathways
[46,47]. Furthermore, in VSMCs 85% of these particles were recycled to
the cell surface from the early endosomes [46,47]. The remaining 15%
were reported to escape the endosomes and reach the cytosol. To
increase the endosomal escape the authors subsequently modiﬁed the
nanoparticles surface with a cationic polymer, poly(L-lysine) (PLL)
[23]. The adhesion of nanoparticles at the cell plasma membrane was
quantiﬁed by AFM in cancer cells. The PLL modiﬁcation led to nearly
ﬁve-fold increase in the interaction force. The modiﬁed particles were
also more rapidly internalized via CME, which allowed considerably
increasing the cellular delivery of a model protein encapsulated in
such nanoparticles [23].
4.3. Silica-based nanomaterials
CME was observed for “template synthesized” silica nanotubes
(SNTs) [48]. Such SNTs provide unique structural features including
inner voids for loading bioactive compounds, end functionalization to
control compound release, and inner and outer surfaces that can be
differentially functionalized for targeting and biocompatibility. The
cationic SNTs (50 nm in diameter and 200 nm long) functionalized
with positively charged aminosilane group at the outer surface were
shown to internalize via CME and reach lysosomes in cancer cells [48].
In another study mesoporous silica-based nanoparticles (ca. 110 nm)
were shown internalize into mesenchymal stem cells and ﬁbroblasts
via a CME but not through caveolae [49].
4.4. Chitosan nanoparticles
The cationic chitosan nanoparticles were shown to utilize CME for
entry in respiratory epithelium(A549) and intestinal epithelium(Caco-2)
cells [50,51]. The nanoparticles used in this study were large (430 nm)
and highly polydisperse (polydispersity index 0.5), which means that
large particles co-existed with small ones, capable of entry into small
vesicles. The selectivity of this formulation towards CME suggests that in
this particular case the chemical composition of the material was more
important than its size in deﬁning the CME entry mechanism. However,
the self-assembled cationic nanoparticles of hydrophobically modiﬁed
chitosan (360 nm, zeta potential ca. +22mV) are using multiple
pathways for cellular entry including CME, caveolae and macropinocy-
tosis [52]. These nanomaterials possibly interacted with the cell
membranes through the 5-β-cholanic acid residues used for hydro-
phobization of chitosan, which altered their trafﬁcking.
4.5. Surface-modiﬁed nanoparticles that target CME
Aspecial case is nanomaterials,whicharemodiﬁed todisplay surface
ligands that utilize CME. Such ligands can include, for example,
mannose-6-phosphate, Tf, nicotinic acid, etc [53]. Notably, the cellular
trafﬁcking of such modiﬁed materials may differ from the trafﬁcking ofcontrast to Tf alone theywere not routed to lysosomes and not recycled
to the cell surface. Instead thesemodiﬁedQDs resided in the perinuclear
endosomes. In another example, QDs (30 nm) modiﬁed with Shiga
Toxinwere entering cells, but unlike the toxin did not accumulate in the
Golgi andwere routed to theendosomes. Such effectwas likely to bedue
to the ability of the QDs to interfere with the cellular trafﬁcking since
they were also shown to alter the transport of unconjugated ligands
(Shiga toxin, Ricin B) [54]. Therefore, in attempts to target nanomater-
ials though speciﬁc ligands and cellular pathways one should take into
account a possibility that such nanomaterials can alter the normal
pathways employed by these ligands. Further examples of those effects
are discussed below for unimers and micelles of Pluronic® block
copolymers [55].
5. Caveolae-mediated endocytosisCaveolae are abundant in muscle, endothelial cells, ﬁbroblasts and
adipocytes and absent in neurons and leukocytes [12]. They are a
subset of lipid rafts, the cholesterol-rich plasma membrane regions
that cluster endocytosis and signal transduction functionalities [56].
The deﬁnitive characteristic of caveolae is the presence of the hairpin-
like membrane protein, caveolin-1, which is necessary for biogenesis
of caveolae. Due to this protein caveolae assume their hallmark ﬂask-
shaped structure (60–80 nm) and can engulf cargo molecules, which
bind to caveolae surface. In addition to caveolin-1, which is present in
most cells, there are other isoforms like caveolin-2 or caveolin-3 (speciﬁc
formuscle) [12]. Other components of the caveolae endocyticmachinery
include proteins like cavin, which induces membrane curvature,
dynamin, which enables vesicle scission, as well as vesicle-associated
membrane protein (VAMP2) and synaptosome-associated protein
(SNAP), which mediate subsequent vesicle fusion, etc. [57,58]. After
budding of the plasma membrane the caveolae vesicles transport and
fuse with caveosomes or MVBs that have neutral pH [59]. This pathway
appears to be slower compared to the CME in vitro but, importantly, at
least in some cases it can bypass lysosomes. Hence, several pathogens
including viruses and bacteria exploit this pathway to prevent lysosomal
degradation [60]. For the same reason this pathway is believed to be
beneﬁcial for cellular delivery of proteins and DNA [61]. The typical
molecules to undergo the caveolae-mediated endocytosis are CTB and
Shiga toxin. These molecules interact with the glycosphingolpids (GSL)
residing in caveolae, such as GM-1 (CTB) and Gb3 (Shiga Toxin) [12].
Both CTB and Shiga Toxin are sometimes used as markers for caveolae.
However, it should be noted that they are not restricted to caveolae and
can also enter through clathrin- and caveolae-independent pathways
described below.
Caveolin-1 is a very promiscuous protein, which binds and promotes
ordering of multiple molecules including lipids (cholesterol, GSL, etc.),
fatty acids, and membrane proteins [60]. Thus, caveolae sequester
multiple ligands responsible for cellular signaling and their downstream
signaling components in close proximity for efﬁcient signal activation and
transduction. Some examples include heterotrimeric G proteins, non-
receptor tyrosine kinases, insulin receptor, platelet derived growth-factor
receptor, and endothelial nitric-oxide synthase (eNOS) [59]. Many of
these molecules seem to directly interact with caveolin. For example,
eNOS binds to the caveolin-1 scaffolding domain and remains inactive
when bound. The ligands, which disrupt this interaction, enable eNOS
activation, which leads to production of nitric-oxide (NO) and increases
vascular permeability [62].
Several nanomaterials are reported to enter cells via caveolae. This
pathway has attracted tremendous attention in nanomedicine, since
it has the ability to bypass lysosomes (although there are few excep-
tions described below). Furthermore, the caveolae-mediated endocy-
tosis is the most prominent transendothelial pathway and thus this
route may be employed for trans-vascular delivery of nanomaterials
[22].
5.3. Polysiloxane nanoparticles
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oxide)-b-poly(methacrylic acid) (PEO-b-PMA) copolymer are unique
hydrogel-likenanomaterials,whichhave swollen cores of a cross-linked
PMA network surrounded by a PEO shell [63]. At extracellular pH 7.4
they have strong negative charge (zeta potential −18 mV), which
decreases at pH 5.0 (−7 mV), while the cl-micelles contract from ca.
150–160 nm to ca. 110 nm. These cl-micelles display selective entry in
cancer cells but donot enter normal epithelial cells due to their ability to
target differences in endocytosis mechanisms between these cells
(Fig. 6) [26]. The internalization of cl-micelles in the cancer cells
proceeds predominately through caveolae-mediated endocytosis. In
conﬂuent normal epithelial cells this endocytosis route is absent at the
apical side [44] and the cl-micelles sequester in tight junction (TJ)
regions of the cell membrane without entering the cells. Furthermore,
contrary to conventional wisdom in cancer cells the cl-micelles bypass
the early endosomes and reach the lysosomes within 30 min. where
they release drug in a pH-dependent fashion. Hence, micelles loaded
with a cytotoxic drug are toxic to cancer cells but not to normal
epithelial cells, where they do not enter [26].
5.2. DOXIL®DOXIL® is a slightly negatively charged PEGylated liposomes
(86 nm), which encapsulate doxorubicin hydrochloride and are used
to treat patients with metastatic ovarian cancer. Surprisingly, little
was known until recently about trafﬁcking of DOXIL® nanoparticles
into cells. Our study presents evidence that these nanoparticles utilize
caveolae-mediated endocytosis to internalize into epithelial cancer
cells [26]. Similarly to the cl-micelles, after the entry through caveolae
the DOXIL® nanoparticles are accumulated in lysosomes, where the
drug is apparently released [26].Fig. 6. Pathways of intracellular trafﬁcking of cl-micelles in normal and cancer epithelial
cells. The cl-micelles carrying a drug, doxorubucin (Dox), in normal epithelial cells were
shown to sequester at the apical surface of the cell membrane near the TJs. However,
during cancer progression the TJs are lost. As a result the cancer epithelial cells internalize
the cl-micelles through caveolae. The cl-micelles are then routed to the lysosomes where
the drug is released through a pH-dependent mechanism. The released drug accumulates
in the nucleus and kills the cancer cells.Amphiphilic self-assembled nanoparticles (ca. 100 nm) of poly(3-
aminopropyl)siolxane (PAPS) modiﬁed with stearic acid residues and
galactose were shown to selectively target caveolae in human aortic
endothelial cells [64]. Even more interestingly, these nanoparticles can
activate eNOS cell signaling and promote NO formation. This strongly
suggests that the nanoparticles disrupt eNOS binding to the caveolin-1
scaffolding domains and provides evidence that synthetic nanomater-
ials can activate signal transduction leading to pharmacological effects
due to interactions with speciﬁc micro-domains at the cell membrane.
5.4. QDs
The effects of surface modiﬁcations on cellular entry were recently
examined using CdSe/ZnS core-shell ellipsoid QDs (diameters 6 nm,
12 nm),whichweremodiﬁedwith PEG, PEG-amineor poly(acrylic acid)
[65]. The resulting QDs-based nanomaterials differed both in surface
charge and size, being neutral (45 nm), positive (20 nm) and negative
(18 nm), respectively. Of the three materials the negatively charged
particles displayed the greatest uptake in skin cells. Moreover, the
negatively charged particles entered the cells primarily through
caveolae, while the neutral and positive particles did not appear to use
this pathway [65].
5.5. Abraxane®
Aside from charge the speciﬁc interactions with the receptor
located in caveolae may deﬁne the cellular entry of nanomaterials.
This is a case of Abraxane®, a nanoparticle albumin-bound (nab) form
of paclitaxel (130 nm) approved by the FDA for metastatic or relapsed
breast cancer [66]. Abraxane® nanoparticles take advantage of
caveolae-mediated transcytosis for efﬁcient delivery of the drug to
the tumor sites [67]. They bind to gp60, the albumin receptor present
in caveolae of endothelial cells, and transport across the vascular walls
to the tumor interstitial spaces [68]. After entering the interstitial
spaces the Abraxane® nanoparticles are captured by SPARC (secreted
protein, acidic and rich in cysteine) that is selectively secreted by the
tumors [69,70]. The SPARC-nanoparticle complexes are taken up in
tumor cells resulting in selective tumor cytotoxicity.
5.6. Surface-modiﬁed nanoparticles that target caveolae
As the signiﬁcance of caveolae for the delivery of nanomaterials has
emerged the attempts have been made to modify the surface of these
nanomaterials to target proteins displayed in caveolae. One such target
was identiﬁed byOh et al. by in vivo quantitative proteomics of caveolae
isolated from tumor lung endothelium [22]. They determined that these
caveolae are enriched with aminopeptidase P (APP). Furthermore, the
monoclonal antibody to APPwas shown to be transported in vivowithin
seconds across endothelium to the lung tissue. Hence, the colloidal gold
nanoparticlesmodiﬁedwith antibody to APPwere found to concentrate
in caveolae of lung microvasculature [22].
Another well known targeting molecule is cyclic RGD peptide,
which binds withαvβ3 integrin receptor located in caveolae. Recently,
Oba et al. used thiolated c(RGDfK)-PEG-b-PLL copolymer for cellular
delivery of the pDNA [71]. This copolymer binds with the DNA
molecules through its cationic PLL chains resulting in core-shell
polyion complex nanoparticles having a core of electrostatically
coupled PPL/DNA and a shell of PEG decorated with the cyclic RGD
peptide. The core of such nanoparticles was additionally stabilized by
cross-linking PLL aminogroups. They were shown to enter cells
through caveolae and localize in the perinuclear regions in HeLa cells.
The increased entry of the RGD-modiﬁed complexes compared to the
non-modiﬁed analogs was accompanied by a superior DNA transfec-
tion efﬁciency in these cells.
6. Clathrin- and caveolae-independent endocytosis 8. Nanomaterials employing multiple pathways for entry
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such cells clathrin- and caveolae-independent endocytosis with ca.
90 nm vesicles has been shown to carry different cargoes including
extracellular ﬂuid, SV40, CTB, glycosylphosphatidylinositol (GPI)-
linked proteins, interlukin-2, growth hormones, etc. For these cargoes
multiple entry pathways appear to exist, which can be regulated
through multiple effectors. Based on the effectors the caveolae- and
clathrin-independent pathways are presently classiﬁed as Arf6-
dependent, ﬂotillin-dependent, Cdc42-dependent and RhoA-depen-
dent [12].All these pathways appear to require speciﬁc lipid
compositions and are dependent on cholesterol. Most of these
pathways are dynamin-independent although the role of dynamin
in some pathways is still being researched.While their later stages are
not yet clearly identiﬁed, they appear to bypass the rab5-poitive early
endosomes. As an example, the GPI-linked proteins are transported
though GPI-anchored protein-enriched early endosomal compart-
ments (GEECs) having a tubulovesicular morphology. Some of these
pathways can also utilize GEEC-independent endosomes and may
interplay with clathrin-dependent endocytic compartments. This is
the case, for example, of the transport of IL-2Rβ, γc cytokine receptor
and the IgE receptor FcεR1 (a major signaling pathway for allergic
reactions)[12,72]. Another subtype is also independent of the GEEC
and requires Arf6 positive endosomes involved in recycling towards
the plasma membrane. This pathway is utilized by the major
histocompatibility class (MHC)-1 protein, which is critical for antigen
presentation and immune response [12,73,74].
There are not many nanomaterials documented to utilize different
subtypes of the clathrin- and caveolae-independent endocytosis. The
examples include nanoparticles and polymersmodiﬁedwith folate [75].
Folate binds to GPI-anchored folate receptor, FRα, which is over-
expressed in tumor cells. The expression of this receptor increases as the
cancer stage advances, which may be important for drug targeting [75].
However, the folate entry in cells is complex andalongwith clathrin- and
caveolae-independent endocytosis it can also involve CME in speciﬁc cell
types [12,76]. Many nanomaterials and polymers were conjugated with
folate including liposomes, protein toxins, biodegradable nanoparticles,
and water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA).
These materials were used targeted intracellular delivery of cytotoxic
drugs, imaging agents and also for boosting immune response [75].
7. MacropinocytosisFig. 7. Cellular entry of PRINT nano- and microparticles. PRINT nanoparticles of all
shapes utilize multiple pathways to gain cellular entry including CME (1), caveolae-
mediated endocytosis (2) and, to a lesser extent, macropinocytosis (3). The shape of the
particles appears to be important in regulating the rate of their cellular entry (not
shown). Cube-shaped PRINT microparticles also utilize multiple routes of cellular entry
but their macropinocytosis appears to be the most prominent.Macropinocytosis is a special case of clathrin-, caveolae- and
dynamin-independent endocytosis, which is initiated by transient
activation of receptor tyrosine kinases by growth factors [24]. The
receptor activationmediates a signaling cascade that leads to changes in
the actin cytoskeleton and triggers formation of membrane rufﬂes.
These membrane rufﬂes protrude to engulf the surrounding ﬂuid and
nutrients in the extracellular milieu [24,77,78]. They can simply melt
with the cell membrane or form an intracellular vacuole, also termed as
a macropinosome [79]. The macropinosomes are larger (0.5–10 µm)
and distinct from other vesicles formed during pinocytosis. Many
particles like bacteria, apoptotic bodies, necrotic cells and viruses can
induce the rufﬂing behavior independently of the growth factors, and
internalize in macropinosomes [24]. Selected nanomaterials were
assumed to utilize this pathway based on their entry dependence on
actin formation inhibitors, such as cytochalasin D [55]. This pathway is
possible for virtually any cell with only few exceptions, such as
macrophages and brain microvessel endothelial cells. In principle it
can internalize large particles with submicron and greater sizes in cells,
which lackphagocytosis. Inmost cases this pathwaymay serve as a non-
speciﬁc entry point and it is discussed further for nanomaterials that can
utilize multiple mechanisms for cellular entry.Most nanomaterials have been shown to exploit more than one
pathway to gain cellular entry. Some examples of such nanomaterials
are discussed below.
8.1. PRINT micro-and nanoparticles
These particles are designed through a top-down lithographic
fabrication method called PRINT (Particle Replication In Non-wetting
Templates) [80]. PRINT technology results in the formation of nearly
monodisperse nanoparticles that have precisely controlled shape, size
and charge. In an elegant study Gratton et al., evaluated internalization
pathways of three different series of micro- and nanoparticles made
from the cross-linked PEG-based hydrogels [81]. All materials were
obtained by UV-copolymerization of the same mixture of monomers in
different PRINT molds and therefore are believed to have the same
chemical composition, but different sizes and shapes. The materials
werepositively charged andhad relatively closezeta potentials (ranging
from +21mV to +41 mV). They included cubic microparticles (2 μm,
3 μm, and 5 μm), cylindrical microparticles (0.5×1 μm, 1×1 μm) and
cylindrical nanoparticles (200×200 nm; 100×300 nm; 150×450 nm).
Surprisingly, all these different particles including the largest ones were
shown to internalize in HeLa cells (Fig. 7). However, the nanoparticles
seemed to enter cells more rapidly than the microparticles. Further-
more, the shape of the nanoparticles also mattered as the extended
cylinders (150×450 nm) entered faster than the equal cylinders of
nearly same volume (200×200 nm), or cylinders of lower volume
(100×300 nm). All nanoparticles appeared to employ multiple path-
ways of entry including CME, caveolae-mediated endocytosis and to a
lesser extent macropinocytosis. It also appeared that CME and caveolae
were more prominent for the entry of nanoparticles compared to the
microparticles. Interestingly, when the charge of these materials was
inverted to negative (−34 mV) by acylating their amino groups their
entry became negligible.
8.2. Pluronic® block copolymers
Another interesting example is the cellular entry of amphiphilic
triblock copolymer of poly(ethylene oxide) (PEO) and poly(propylene
oxide) (PPO), Pluronic® P85 (P85) [82]. Below the critical micelle
concentration (CMC) this copolymer exists as single molecule chains
(unimers) and above CMC forms 14.6 nm aggregated micelles with a
hydrophobic PPO core and hydrophilic PEO shell. Both the copolymer
and micelles are electrostatically neutral. This copolymer was shown
to utilize multiple pathways to gain entry in mammalian cells
8.4. Poly(amidoamine) (PAMAM) dendrimers
Fig. 8. The entry mechanisms of Pluronic® block copolymers in (A) epithelial cells and
(B) neurons. A. In cells displaying the caveolae pathway Pluronic® P85 unimers enter
through caveolae-mediated endocytosis (1). In cells devoid of caveolae, such as conﬂuent
MDCK cells, the block copolymer unimers can also enter through caveolae-independent
pathways (2). Once the concentration of the block copolymer increases above the CMC the
micelles are formed, which enter through the CME (3). Under these conditions the block
copolymer inhibits the caveolae-mediated endocytosis. B. In primary neurons (also devoid
of the caveolae) the Pluronic® P85 unimers enter the cell body from where they undergo
anterograde trafﬁcking to the axons/dendrites.
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unimers internalize predominantly through caveolae-mediated en-
docytosis, however, in cells devoid of caveolae the copolymer exploits
caveolae- and clathrin-independent endocytosis. Interestingly the
unimers were shown to bypass early endosomes/lysosomes, transport
to endoplasmic reticulum, and eventually reach mitochondria [21].
Furthermore, the copolymer succeeds in entering nearly impenetrable
cells, such as primary brain endothelial cells and primary neurons
where the copolymer moves anterograde from cell body to axons/
dendrites (Fig. 8B). On the contrary P85 micelles internalize
exclusively through CME [55]. Furthermore, at concentrations above
CMC P85 inhibits caveolae-mediated endocytosis while having little
or no effect on CME [55].
8.3. PS nanoparticles
Contrary to Pluronic® micelles PS nanoparticles do not disintegrate
upon dilution. However, their cellular trafﬁcking can also depend on
their size. For example, Lai et al. have recently shown that negatively
charged 43 nm PS nanoparticles can enter HeLa cells through CME and
reside in the endo-lysosomal compartment [83]. The reduction of the
nanoparticle size to 24 nm resulted in a shift of the entry mechanism to
clathrin- and caveolae-independent pathway. Furthermore, it also
altered the processing of the nanoparticles, which in this case bypassed
lysosomes and localized near the perinuclear space. Recent work also
evaluated the entry of 200 nm positively charged (amine-modiﬁed) or
negatively charged (carboxylate-modiﬁed) PS nanoparticles [26].
Independent of their charge such nanoparticles were shown to enter
caveolae-deﬁcient ﬁbroblasts as well as conﬂuent MDCK cells that lack
apical caveolae.Dendrimers are repeatedly branched, monodisperse and usually
highly symmetric compounds, which have been widely researched for
delivery of therapeutic and diagnostic agents [84]. They have a large
number of surface groups that can immobilize drugs, enzymes, targeting
moieties or other imaging agents. The amine-modiﬁed cationic dendri-
mers or carboxylate-modiﬁed anionic PAMAM dendrimers were shown
to utilize multiple routes of entry inside Caco-2 and B16f10 melanoma
cells.[85,86]. The entry mechanisms appeared to depend on the
dendrimer generation. For example, a lower generation amine-modiﬁed
dendrimerG2wasentering cells primarily throughCME,while thehigher
generation dendrimer G4 utilized multiple routes [85,86]. The positively
chargeddendrimershavebeen showntoenter early endosomesand then
route towards the lysosomes within 20 min. [85,87]. In contrast, the
negatively charged dendrimers appeared to accumulate in lysosomes at
later points. Finally, in experiments studying the transport of the
dendrimers across the polarized cell monolayers both cationic as well
as anionic dendrimers were shown to open up the TJ and cross the
monolayers by a paracellular route as well as transcellular route [88].
8.5. Non-viral gene delivery agents and DNA
Nanosized complexes of cationic lipids with DNA (“lipoplexes”) or
synthetic polycations with DNA (“polyplexes”) have been used for gene
delivery. Clearly, the cellular trafﬁcking of such nanomaterials can
strongly depend on their composition, size, shape, and surface
characteristics. Since the polyelectrolyte complexes of DNA can undergo
multiple structural transitions [89] it is hard to precisely control their
characteristics, especially in the cellular environment. As a result there
are often conﬂicting reports involving such systems. For example, one
study reported that cellular entry of polyethyleneimine (PEI)-based
polyplexes depends both on the cell type as well as PEI structure [90].
More speciﬁcally, it was shown that polyplex based on branched PEI in
the monkey kidney cells (COS-7) predominantly utilize CME [91] while
in HeLa cells both CME and caveolae-mediated endocytosis. In contrast,
polyplex based on linear PEI appeared to internalize through CME
independently of the cell type. On the contrary, another study suggested
that linear PEI/DNA polyplex use both pathways while branched PEI/
DNA polyplex as well as polyamidoamine (PAMAM) dendrimer/DNA
polyplex use only caveolae [86]. This clearly contradicts to another
report that branched PEI-based polyplexes use both CME and caveolae-
mediated endocytosis [92]. Our own data suggested that polyplexes
based on linear PEI or PEG-g-PEI graft copolymer utilize both pathways
[93]). Similarly, polyplexes based on PEG-g-PLL graft copolymer were
also shown to utilize CME, caveolae-mediated endocytosis and macro-
pinocytosis [94]. Lipoplexes can enter cells through multiple pathways
and their entry depends on the lipoplex composition. For example,
lipoplexes based on DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-tri-
methylammoniummethyl sulfate) [92] and Lipofectamine were shown
to internalize by CME. In contrast, DMRIE-C (1,2-dimyristyloxypropyl-3-
dimethyl-hydroxy ethyl ammonium bromide)-based lipoplex interna-
lizes through caveolae [95]. However, following the initial internaliza-
tion stages both pathways appear to converge towards the late
endosomes or lysosomes, where DNA delivered with Lipofectamine-
and DMRIE-based lipoplexes is found. However, it should be noted that
blocking of the lysosomal transport did not improve the transfection
yield, which suggests that the DNA may utilize a different pathway to
reach its nuclear destination.
An ideal gene delivery agent after initial uptake must escape
degradation in lysosomes, and enable translocation of DNA to the
nucleus. In a classic study Bausinger et al. followed the intracellular
trajectory of linear PEI/DNA polyplexes by ﬂuorescence live cell imaging
[96]. They were able to show that at the initial stage polyplexes attached
to the cell membrane are co-localized with actin ﬁlaments, while at
the later stage they appear to move along the microtubules. A similar
observation was made by Suh et al. who suggested that branched PEI/
DNA polyplexes entrapped in endosomes are transported by motor-
8.6. Surface-modiﬁed nanoparticles that target multiple pathways
Fig. 9. DNA delivery to the nucleus. 1). PEI/DNA complexes internalize into cells utilizing
actin-dependent pathway. 2). The endosomes containing PEI/DNA complexes travel inside
the cytoplasm along the microtubules and reach the perinuclear space where the DNA is
released through an unknownmechanism. 3). An alternativemechanismmay involve direct
release of PEI/DNA complex from endosomal/lysosomal compartments, followed by the
transportof the complex through thecytoplasmand to thenucleus. 4). TheDNA import to the
nucleus can be enhanced by activating cellular signaling by Pluronic® block copolymers. In
this case Pluronics® bindwith the cellmembranes and activate phosphorylation of IκB by an
IκB-kinase (not shown). Thephosphorylated IκBdissociates from its complexwithNFκB. The
released active NFκB enhances transport of DNA into nucleus in a promoter-dependent
fashion.
Fig. 10. Targeting of stimuli-sensitive double-targeted liposome to tumors. A. The surface
of the drug-loaded liposome ismodiﬁedwith a cell-penetratingpeptide (CPP) attached via
relatively short PEG chains. This peptide is masked by long PEG chains anchored to the
liposome surface via pH-sensitive cleavable links. Some of the long PEG chains are
decoratedwith theantibodyspeciﬁc to the tumorantigen. Theantibody is exposed and can
bind with the antigen at the tumor cell surface. B. Inside the acidic microenvironment of
the tumor the long PEG chains and the antibody conjugates are detached from the
liposome resulting in exposure of the CPP. The CPP interacts with the cell membrane and
facilitates endocytosis of the drug-loaded liposomes into tumor cells.
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towards the nucleus [97]. They also speculate that after reaching the
perinuclear space theDNAcandiffuse to the nucleus (Fig. 9). This appears
to contradict a widespread belief that DNA can be released directly to
cytoplasm from endosomal/lysosomal compartments through destabili-
zation of these compartments by PEI (“proton sponge” hypothesis) [98].
The nuclear import of the DNA is cell-cycle dependent and is one of the
most challenging barriers for non-viral gene delivery. Surprisingly, it was
recently shown that synthetic polymers can help to overcome this barrier
through the activation of speciﬁc cellular trafﬁcking machinery [93]. In
particular, Pluronic® block copolymers added to cells enhance uptake and
nuclear import of plasmid DNA delivered with polyplexes (Fig. 9).
Notably, this effect appears tobedue to theabilityof theblockcopolymers
toactivateNFκBsignaling in thecells.NFκBwas showntobind tocytosolic
DNA and facilitate its transport to the nucleus through nuclear import
machinery [99]. Consequently, the effects of the Pluronic® copolymer
were dependent on the DNA promoter [93]. The copolymer enhanced
nuclear import of pDNA containing NFκB binding sites, but had no effect
on the import of pDNAwithout these sites. Interestingly, Pluronics® have
been also shown to increase transcription of the DNA delivered into the
nucleus in transiently and stably transfected cells [100]. This phenome-
non may also involve activation of the NFκB transcription machinery.
Overall, the interest in the effects of the Pluronics® on gene delivery has
been recently propelled by ﬁndings that these copolymers can greatly
enhance the delivery of the naked DNA in vivo [101]. Very little is known
how the DNA alone is transported into the cells, however, it was shown
recently that naked DNA in serosal cells in vivo can internalize through
macropinocytosis [102].To increase cellular delivery of various nanomaterials such as
liposomes, iron nanoparticles, siRNA- and DNA-containing poly-
plexes, etc., their surfaces were modiﬁed with cell-penetrating
peptides (CPPs), also known as Protein Transduction Domains
(PTDs) [103,104]. Such ligands usually employ multiple pathways
for intracellular trafﬁcking. They represent small cationic polypep-
tides of from 10 to 30 amino acids. Some of the best characterized
CPPs are TAT peptide, penetratin, transportan, poly-arginine, rabies
virus glycoprotein (RVG) peptide, etc. For example, human immuno-
deﬁciency virus TAT fusion protein (N30 kDa) and TAT peptides (1 to
5 kDa) enter cells by cholesterol-dependent macropinocytosis as the
primary entry mechanism [105,106]. Their transport does not seem to
involve CME or caveolae. Yet, since the TAT peptide was shown to
enter cells even when macropinocytosis was inhibited, alternative
mechanisms were also postulated, which involve direct transloca-
tion of the peptide across the plasma membrane [107]. In a recent
example, Torchillin et al. modiﬁed PEGylated liposomes and PEG-
polyphosphatidylethanolamine micelles with 1) the targeting anti-
9.1. Effect of the particle charge
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TAT peptide hidden within this layer [108]. Such double functionality
is believed to ensure delivery of the liposomes to the target cells,
where the antibody layer is cleaved and the TAT peptide exposed,
which enables subsequent particle delivery into cells (Fig. 10). In
another example the RVG peptide was shown to cross the brain
endothelial cells and subsequently enter the neuronal cells using
nicotinic acetylcholine receptor (nAchR) [109]. This peptide was
further fused with nonamer arginine residues to form complexes with
siRNA, which could deliver siRNA to the brain and enable protection
against fatal viral encephalitis in mice. In a subsequent study, this
peptide was conjugated to PAMAM dendrimers through a PEG spacer
and then complexed with DNA, yielding polyplexes with RVG
functionalities exposed at the surface [110]. These polyplexes were
shown to internalize in the brain endothelial cells through CME and
caveolae-mediated endocytosis, and deliver the DNA to the brain in
vivo. Notably, their transport mechanism appeared to be more
dependent on the GABAB receptor than on nAchR.
In addition to CPPs, various other ligands were used to enhance
cellular delivery of both nanoparticles and water-soluble polymers.
For example, the HPMA copolymer was recently modiﬁed with an
antibody against prostate speciﬁc membrane antigen (PSMA) [111].
The cellular internalization of such antibody-modiﬁed HPMA in the
prostate cancer cells overexpressing PSMA was greatly enhanced
compared to the copolymer conjugated to a non-speciﬁc IgG. The entry
of the antibody-HPMA conjugates involved CME, macropinocytosis, as
well as clathrin- and caveolae-independent endocytosis. At the later
stages of trafﬁcking the conjugate appeared to be routed to the late
endosomes. Muro et al., have also showed that in polystyrene particles
of micron and submicron sizes of different shapes (spherical or
elliptical) can be internalized into endothelial cells by targeting
intercellular adhesionmolecule 1 (ICAM-1) [112]. The authors suggest
such particles enter through caveolae-, clathrin-, and macropinocy-
tosis-independent pathway, which, however depends on actin.
Furthermore, the ICAM-1-targeted micron sized particles remained
in the prelysosomal compartments whereas the submicron sized
particles reached the lysosomes more rapidly. Moreover, it appeared
that particle shape inﬂuenced the rate of endocytosis, with spheres
internalized more rapidly than elliptical disks.
9. Generalizations and future directionsFuture drug delivery systems aim to deliver drugs not only precisely
to a speciﬁc cell population but often to a speciﬁc intracellular
compartment. Therefore, it has become increasingly necessary to
delineate mechanism(s) of intracellular trafﬁcking of synthetic nano-
materials that can serve as the carriers for drugs or themselves act as
therapeutic or imaging agents. Furthermore, it is quintessentially
important to learn how to direct the nanomaterials towards selected
intracellular compartments through engagement of speciﬁc cellular
trafﬁcking machinery(ies). The growing body of research suggests that
nanomaterials transport in cells depends on structure and physico-
chemical characteristics of nanomaterials (size, shape, charge, hydro-
phobicity, etc.), biospeciﬁc interactions between biological moieties
decorating nanomaterials with cells, as well as peculiarities of the in
endocytic machinery present in different cell types. The complex
interplay of nanomaterial-cell interactions results in intracellular
sortingof nanomaterials towardsdifferentdestinations and canmediate
activation of cellular signaling. Given the diversity of nanomaterials and
cells used in the trafﬁcking studies the ﬁnding of common factors that
deﬁne intracellular transport of the nanomaterials has become a
formidable task. Yet in this paper we make an attempt to delineate
such factors and make recommendations for future research.First, the cellular entry deﬁnitely depends on the nanomaterial
charge. At present the majority of reports suggest that positively
charged nanomaterials predominantly internalize through CME with
some fraction utilizing macropinocytosis. Examples include cationic
nanoparticles of very different origin — stearylamine-coated PEG-co-
PLA, PLGA modiﬁed with PLL, amino group-modiﬁed SNTs, chitosan,
etc [41,42]. However, there are some exceptions, most notably, PEI-
based polyplexes, which are strongly cationic and yet may utilize
multiple pathways including caveolae-mediated endocytosis [92]. It
should be noted, however, that such complexes are usually formu-
lated with excess of polycation and in cellular environment may
additionally bind serum proteins, which can drastically affect their net
charge and composition and alter trafﬁcking. Furthermore, the large
excess of polycations used in cell transfection experiments may also
disturb the normal cell trafﬁcking mechanism. Another exception
involves positively charged PRINT particles which can utilize multiple
pathways to gain cellular entry [81].
On the other hand, negatively charged nanoparticles, such as
DOXIL®, cl-micelles, and QDs, are more likely to utilize caveolae-
mediated endocytosis [26,65]. Exceptions include some carboxylate-
modiﬁed PS nanoparticles and negatively charged PLGA nanoparti-
cles, which can enter cells through caveolae-independent pathways
[46,47]. Since cell membranes are generally negatively charged, it is
widely believed that negatively charged nanomaterials should
internalize slower compared to their positively charged counterparts.
This appears to be a case of negatively charged PRINT nanoparticles.
Yet a striking exception is negatively charged QD, which were shown
to internalize much faster compared to neutral or positively charged
QD [65]. It is unclear from literature whether neutral nanomaterials
show any preference for speciﬁc cellular entry routes. In case of
neutral Pluronic® micelles the CME pathway appears to be the main
route of entry. However, this may be due to the ability of this block
copolymer to inhibit caveolae-mediated endocytosis at micellar
concentrations [55].
9.2. Effect of the particle size
It has long been believed that the size of nanomaterials may play a
paramount role in their inclusion within different endocytic vesicles
that greatly vary in sizes. Speciﬁcally, theneed to keep theparticle small,
between10 to 100 nm, to enter the endocytic vesicleswaspostulated by
many and became a foundation for current deﬁnition of nanomedicine
by various agencies worldwide. However, while the small size may be
beneﬁcial for a rapid entry into cells there appears to be no size cut off
limit up to at least 5 µm to gain cellular entry of somematerials through
pinocytosis. The largest particles are, perhaps, more likely to enter cells
through macropinocytosis as was suggested for PRINT microparticles
[81]. Other notable examples of size effects are negatively charged PS
nanoparticles, which showed CME based entry for 43 nm particles and
caveolae-mediated entry for 25 nm particles [83]. A major problem in
dissecting the effects of the size is high polydispersity of many
nanomaterials. However, as discussed above in some cases, such as
highly polydisperse chitosan nanoparticles [51], the size of the particles
may play a much lesser role in deﬁning the entry pathway than the
chemical composition of the nanomaterial.
9.3. Effect of the particle shape
The effects of the particle shape were previously described for
phagocytosis [113]. However, to best of our knowledge for pinocytosis
the PRINT nanoparticles remain the only clear example of relationship
between the particle geometry and cellular entry [81,114]. Clearly, to
deﬁne such effects the nearly monodisperse nanoparticles need to be
manufactured. Other than shape, however, the compressibility of the
material may matter for soft nanoparticles, such as nanogels and the
like [114].
comparable with the speciﬁc interactions of the ligands attached to
polymers and nanomaterials. One obvious remedy could be, ﬁrstly, to
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Perhaps, themost exciting, challenging and poorly explored area is
the relationship between the nanomaterial cellular trafﬁcking and cell
type. Few examples discussed above underscore that the cell typemay
be critical in deﬁning the nanoparticle entry and ﬁnal destination in
the cells. Notably, it even appears that the differential endocytic
pathways in normal and tumor cells may be a gateway for selective
targeting of novel nanomaterials into tumors [26]. Most studies of the
nanomaterial trafﬁcking performed so far did not emphasize the link
between cell origin and availability of various endocytic pathways
present in these cells. At the same time, the known cellular pathways
may be differentially presented or even totally absent in selected cell
types depending on the cell phenotype, and, in some cases, even
growing conditions, such as cell density, presence of growth factors,
etc. Obviously, in-depth understanding of the cell biology and it's
relation to nanomaterials science is most critical for advancement of
this area of nanomedicine and drug delivery.
9.5. Understanding sub-cellular trafﬁcking of nanomaterials
Delivery of polymers and nanomaterials to speciﬁc intracellular
compartments, e.g. different cellular organelles, cytoplasm etc., has
become increasingly popular due advent of drugs that target speciﬁc
regions within the cells. For example, recently, a hexadentate-PLGA
copolymer chemically conjugated to a selective MAPK inhibitor was
shown to internalize and release drug in the cytosol of tumor cells [115].
Pluronic® block copolymers can reach mitochondria where they exert
unique pharmacological activities like ATP depletion in multidrug
resistant cancer cells [116]. Somematerials like cl-micelles canbe routed
to lysosomes and employ lysosomal pH as a trigger for release of a
cytotoxic drug precisely within the cancer cells [26]. On the contrary,
non-viral gene delivery systems, should bypass lysosomes to prevent
degradation of DNA, siRNA or antisense oligonucleotides.
Therefore, the studies of cell trafﬁcking should extend beyond the
initial entry point of the nanomaterials towards precise deﬁnition of the
entire nanomaterial cellular itinerary. In such studies one must be
careful not to misinterpret the initial stages of entry as a guarantee for
the nanomaterial's ﬁnal destination. Thus, caveolae-mediated endocy-
tosis is still broadly believed to bypass lysosomes but in certain cases
such as cl-micelles the entry through this pathway may destine to the
lysosomes [26]. In another case Pluronic® unimers enter through
caveolae and then pass through ER to mitochondria — the pathway,
which still is quite peculiar for biologicalmolecules [21]. Needless to say
the impetus should be given in the future to gain fundamental
understanding of sorting of nanomaterials. One might even speculate
that certain motif(s) (e.g., hydrophobic or chargeable groups), within
the synthetic polymer might govern its sorting to a speciﬁc compart-
ment and on removing such motif the trafﬁcking may change. Well
known analogs of such motifs are present in proteins (e.g. KDEL amino
acid sequence targeting the ER, or GPI anchor on theplasmamembrane)
[117,118]. However,we alsoneed to realize that syntheticwater-soluble
polymers and nanomaterials can exploit pathways that are unique for
biomacromolecules and are not fully explored.
9.6. Understanding active targeting of nanomaterials
The concept of active targeting of nanomaterials using antibodies,
polypeptides, aptamers and other targeting groups, has generated
tremendous interest and on a surface appears to be simple [3,84]. Itmay
be more complicated than it is seems because both water-soluble
polymers and nanoparticles are large enough to engage in considerable
non-speciﬁc surface interactions with cells and organelles that may bemodify the surface of the nanoparticle with “inert” polymer that would
haveminimal interactionswith the cells, and, secondly, to attach one or
multiple targeting ligand(s) at the inert layer to allow for speciﬁc
binding of the targeting ligands with their receptor [4]. The problem,
however, is in identifying such an “inert” polymer tomask the surface of
the carrier. The current “gold standard” is PEG but there are clear
indications that even this polymer attached to nanomaterials can
activate complement, and otherwise engage the body immunity [119].
With this caution, there are several exciting examples of using
targeting ligands for delivery of nanomaterials into cells. Some of these
examples, e.g. APP-modiﬁed gold nanoparticles [22], RVGpeptide/siRNA
complexes [109,110], TAT-modiﬁed liposomes [104] and others are
discussed above. Such biospeciﬁc, surface-modiﬁed nanomaterials are
rapidly internalized in cells. Conventional wisdom assumes that they
might follow a similar intracellular itinerary as the ligands used for their
modiﬁcation.However, thismightnot be the case, as illustrated aboveby
an example of QD, which are modiﬁedwith Tf or CTB [54]. Furthermore,
Pluronic® block copolymers were shown to inhibit caveolae-mediated
endocytosis at higher concentrations (0.01% and above) [55]. Evenmore
interestingly they have shown an ability to enhance nuclear import of
polyplex-delivered DNA [93]. By interacting with speciﬁc membrane
micro-domains, such as caveolae, polymers and nanomaterials may
affect multiple signal transduction pathways. Another example of this
sort is polysiloxane nanoparticles that appear to activate of eNOS
signaling [64]. These examples suggest that polymers andnanomaterials
can also inﬂuence intracellular transport. It is expected therefore that
introduction of surface modiﬁcations in nanomaterial may result in a
complex trafﬁcking behavior, as nanomaterials may have an intrinsic
ability to affect select cellular functions.
10. ConclusionsUnderstanding the cellular entry of nanomedicines has become
central to the ﬁeld of drug delivery. Nanomedicines utilize endocytic
vesicles or endosomes which in turn employ complex trafﬁcking
machinery to sort towards a speciﬁc intracellular destination. We
categorized nanomedicines that utilize select endocytosis pathways to
gain intracellular access. Based on examples reported one can
conclude that charge, shape, material composition, and surface
chemistry are critical physicochemical parameters that determine
cellular entry of nanomedicines through deﬁnitive endocytic route(s).
Reports now suggest that nanomedicines can also inﬂuence the
cellular signaling by interacting with membrane micro-domains
which home different signaling components (receptors, signal
activators, transducers). In addition, biospeciﬁc ligands decorated on
a nanomedicine to target it towards a select route may actually have
different trafﬁcking as compared to the ligand alone. The ﬂedgling
cross-disciplinary area of endocytosis of nanomedicines is at the
interface of biology andmaterial science andmay bring the next wave
of signiﬁcant technological breakthrough. To reach this goal, certain
caveats need to be addressed. It should be noted that various
laboratories utilize different cell types, use heterogeneous nanomedi-
cines and different tools to study trafﬁcking mechanism-thus
obfuscating the efforts to make deﬁnite, generalizations. To better
understand this area, we recommend that each study usemultiple cell
types, utilize homogeneous nanomedicines and employmultiple tools
to dissect trafﬁcking. Another challenge is that these generalizations
are based mostly on in-vitro studies. Thus, developing assays to study
the complex process of endocytosis of nanomedicines in vivo remains a
key challenge for the future success of this ﬁeld. We hope that this
review will assist a diverse audience of readers and will facilitate
future studies to develop efﬁcient nanomedicines for diagnosis and
treatment of cancer and other diseases.
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